Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Stomach Cancer
70%
Helicobacter Pylori
67%
Narrow Band Imaging
66%
Endoscopy
55%
Neoplasm
52%
Endoscopic Submucosal Dissection
43%
Pylorus
33%
Diagnosis
26%
Magnifying Endoscopy
25%
Polyp
24%
White Light Endoscopy
23%
Stomach Mucosa
22%
Adenoma
22%
Confocal Laser Scanning Microscopy
21%
Lymphatic Follicle
21%
microRNA
21%
Ulcer
19%
Bleeding
17%
Crohn's Disease
16%
Ulcerative Colitis
16%
Chromoendoscopy
14%
Disease
14%
Image Enhanced Endoscopy
13%
Computer Assisted Tomography
13%
Proton-Pump Inhibitor
13%
Gastrointestinal Stromal Tumor
13%
Metastatic Carcinoma
13%
Echography
13%
Colonoscopy
13%
Mucosa
12%
Eradication Therapy
11%
Pepsinogen
10%
Omeprazole
10%
Pancreas Islet Cell Tumor
10%
Sunitinib
10%
Leiomyosarcoma
10%
Endoscopic Ultrasound Guided Fine Needle Biopsy
10%
MALT Lymphoma
10%
Interventional Ultrasonography
10%
Venous Ulcer
10%
Helicobacter Infection
10%
Cancer
10%
Edoxaban
10%
Downregulation
10%
Duodenum Ulcer
10%
Inflammatory Disorder
10%
Eosinophilic
10%
Jejunum Ulcer
10%
Iron Supplement
10%
Esophageal Web
10%
Pancreas Tumor
10%
Esophagus
10%
Plasma Cell Granuloma
10%
Macrogol
10%
Anisakiasis
10%
Heat Shock Protein 70
10%
DNA Methyltransferase 3A
10%
Colon
10%
Hepatocellular Carcinoma
10%
Antiulcer Agent
10%
Colorectal Tumor
10%
Colorectal Adenoma
10%
Bevacizumab
10%
Pyogenic Granuloma
10%
Ascorbic Acid
10%
Pancreas Adenocarcinoma
10%
Methylation
10%
Cholangitis
10%
Scoring System
10%
Chronic Kidney Disease
10%
Inflammatory Bowel Disease
10%
Colon Mucosa
10%
Cancer Susceptibility
10%
Intestine Preparation
10%
Atezolizumab
10%
Common Bile Duct
10%
Bile Duct
10%
Lenvatinib
10%
Overall Survival
10%
Capillary Network
10%
Malignant Neoplasm
10%
Final Diagnosis
9%
Surgery
8%
Cancer Risk
8%
Deoxycytidine Kinase
8%
DNA Methylation
8%
Hazard Ratio
7%
Identified Patient
7%
Lymphocyte
7%
Lavage
7%
Adverse Event
7%
Prevalence
7%
Diagnostic Imaging
7%
Morphology
6%
Erythema
6%
Progression Free Survival
6%
Gastrointestinal Tract
6%
Stomach Acid Secretion
6%
Stomach Ulcer
6%
Diagnostic Accuracy
5%
Keyphrases
Atezolizumab Plus Bevacizumab
32%
Endoscopic Features
21%
Helicobacter Pylori Eradication
21%
Single Shot multibox Detector
21%
Advanced Hepatocellular Carcinoma
21%
Clinical Outcomes
21%
HRH2
21%
Magnifying Endoscopy with Narrow-band Imaging
15%
Non-cancer
15%
Atrophy
13%
Methylation
13%
Minor Allele
13%
Fundic Gland Polyp
12%
Hyperplastic Polyp
12%
Chromoendoscopy
12%
CDKN2A Methylation
12%
Aberrant Methylation
12%
Gastric mucosa
12%
Methylation Status
12%
Aberrant DNA Methylation
12%
White Light Endoscopy
11%
Light Blue Crest
10%
Anti-PD-1 Antibody
10%
Regorafenib
10%
TAS-116
10%
Oral Inhibitors
10%
Efficacy Predictor
10%
Second-look Endoscopy
10%
Well-differentiated Pancreatic Neuroendocrine Tumor
10%
Metastatic Gastric Cancer
10%
Randomized Placebo-controlled Trial
10%
Bovine Lactoferrin
10%
Chronic Hepatitis C
10%
Molecular Subtypes
10%
Feature Impact
10%
Full-endoscopy
10%
Gastrointestinal Subepithelial Lesions
10%
Endoscopic Ultrasound-guided
10%
GI Tumors
10%
Consensus Guidelines
10%
Epigenome Evolution
10%
Interventional Endoscopic Ultrasonography
10%
Non-neoplastic
10%
Confocal Laser Endomicroscopy
10%
Ulcerative Colitis-associated Neoplasia
10%
Leukocyte DNA
10%
IGF2 DMR
10%
Probe-based Confocal Laser Endomicroscopy (pCLE)
10%
Primary Lesion
10%
Depressed Lesion
10%
Clinical Pathological Characteristics
10%
Submucosal Hematoma
10%
Distal Colon
10%
Bowel Dysfunction
10%
Blue Laser Imaging
10%
Gemcitabine Sensitivity
10%
Deoxycytidine Kinase
10%
Prior Exposure
10%
Motesanib
10%
Glue Therapy
10%
Transabdominal
10%
Food Taste
10%
SCN10A
10%
Individual Response
10%
Response to Food
10%
MiR-429
10%
Feasibility Trial
10%
Anti-oncomir
10%
Gene Aberrations
10%
Plummer-Vinson Syndrome
10%
Esophageal Web
10%
Iron Therapy
10%
Gastric Epithelium
10%
3′-untranslated Region (3′-UTR)
10%
Esophagus
10%
Cabozantinib
10%
Field Effect
10%
Inflammatory Myofibroblastic Tumor
10%
Microarchitecture
10%
Small Maf
10%
Pre-microRNA
10%
Differentiated Type
10%
Advanced Gastric Cancer
10%
Elderly Gastric Cancer
10%
Comorbidity Index
10%
Rs3746444
10%
Minimal Change Esophagitis
10%
Hamartomatous Polyposis Syndromes
10%
Fosaprepitant
10%
Aprepitant
10%
Degree of Infection
10%
Small Bowel Polyps
10%
Combination Therapy
10%
DNMT3A
10%
MicroRNA-325
10%
Ramucirumab
10%
Pancreatic Neoplasms
10%
Mucosal Morphology
10%
Epigenetic Field Defect
10%
Field Defect
10%
Pharmacology, Toxicology and Pharmaceutical Science
Stomach Cancer
100%
Helicobacter Pylori
47%
Chemotherapy
36%
Bevacizumab
34%
Malignant Neoplasm
33%
Lactoferrin
32%
Helicobacter Infection
32%
Liver Cell Carcinoma
32%
Atezolizumab
32%
Adenoma
24%
Placebo
21%
Imatinib
21%
Gastrointestinal Stromal Tumor
21%
microRNA
21%
Colorectal Tumor
21%
Adverse Event
21%
Neoplasm
20%
Overall Survival
18%
Alpha Fetoprotein
16%
Polyp
15%
Disease
13%
Colorectal Adenoma
13%
Gastric Mucosa
12%
microRNA 31
12%
Proton Pump Inhibitor
11%
Combination Therapy
11%
Duodenum Ulcer
11%
Inflammation
10%
Regorafenib
10%
Chronic Hepatitis C
10%
Randomized Controlled Trial
10%
Epidermal Growth Factor Receptor 2
10%
Gamma Urogastrone
10%
Trastuzumab
10%
Folinic Acid
10%
Metastatic Colorectal Cancer
10%
Ethanol
10%
Pancreas Cancer
10%
Anticoagulation Therapy
10%
Motesanib
10%
Sunitinib
10%
Colon Polyposis
10%
Vascular Disease
10%
Lenvatinib
10%
Jejunum Ulcer
10%
Cabozantinib
10%
Heat Shock Protein 70
10%
Intestine Tumor
10%
Meglumine
10%
Aprepitant
10%
Fosaprepitant
10%
DNA Methyltransferase 3A
10%
Ramucirumab
10%
Duodenum Disease
10%
Comorbidity
10%
Cancer Susceptibility
10%
Infection
10%
Ulcer
8%
Progression Free Survival
7%
Bleeding
7%
Metaplasia
6%
Anorexia
6%
Histamine H2 Receptor
6%
microRNA 143
6%
Stomach Ulcer
6%
Omeprazole
6%
Insulin-Like Growth Factor 1
5%
Tetrazolium Blue
5%
Rectum Adenoma
5%
Prevalence
5%
Adenocarcinoma
5%
Gastritis
5%
Familial Adenomatous Polyposis
5%
Gallbladder Tumor
5%
Cholesterol Stone
5%
Carcinoma
5%
Pepsinogen I
5%